Bioinformatics and experimental validation have revealed 179 shared differentially expressed genes (DEGs) between chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), ...

NG-350A is a next generation, systemically administered immunotherapy designed to drive intratumoral expression of a CD40 agonist monoclonal antibody in both ...

When exposed to antibiotics, approximately one out of every 10 8 -10 9 bacteria develops resistance due to spontaneous ...

This paper explores the potential of mitochondrial-associated programmed-cell-death (mtPCD) patterns as biomarkers for predicting the prognosis of ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver ...

Those with piebaldism have areas of lighter-than-normal skin and hair due to the absence of pigment. Read more at ...

Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today announced that initial Phase 1 clinical results with PLX-4545, a selective IKZF2 molecular glue degrader, ...

The B7-33 peptide, a derivative of the H2-relaxin hormone, has garnered attention in scientific research due to its potential ...

PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...

REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, ...

VY1706 is an IV-administered gene therapy for Alzheimer's disease that combines a potent siRNA construct to decrease the expression of tau with an IV ... decline in Alzheimer's disease. VY7523 is ...